Skip to main content
Menu
US

HTRF Human and Mouse Phospho-CDK2 (Tyr15) Detection Kit, 500 Assay Points

This HTRF kit enables the cell-based quantitative detection of phosphorylated CDK2 (Cyclin-Dependent Kinase 2) at Tyr15, which is an inhibitory phospho-site essential for maintaining genome integrity and preventing DNA damage during the S phase.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Part number: 64CDK2Y15PEG
Unit Size: 500 Assay Points
List price: USD 2,147.00
Your price:
USD 2,147.00
USD 2,147.00 /each
Part number: 64CDK2Y15PEH
Unit Size: 10,000 Assay Points
List price: USD 12,490.00
Your price:
USD 0.00
USD 12,490.00 /each

Overview

This HTRF cell-based assay conveniently and accurately detects phosphorylated CDK2 at Tyr15. ​​​​​​​

CDK2 (Cyclin-Dependent Kinase 2) is a member of the subfamily of CDKs that coordinate cell cycle progression in mammalian cells (also including CDK1, CDK4, and CDK6). CDK2 is activated by interaction with Cyclin E and Cyclin A during the late G1 phase and S phase respectively, and is also regulated by two major phospho-sites. Phosphorylation at Tyr15 by the kinase Wee1 is inhibitory by preventing ATP binding, whereas Tyr15 dephosphorylation by the phosphatase Cdc25A and phosphorylation at Thr160 by CAK (CDK Activating Kinase) is required for its full activity.

CDK2 inhibitory phosphorylation at Tyr15 is essential for maintaining genome integrity and preventing DNA damage during the S phase. The Wee1/Cdc25A axis is therefore an attractive target for cancer therapy and may represent a unique approach to sensitize cancer cells with hyperactive CDK2.

Specifications

Assay Points
500
Assay Target Type
Kit
Assay Technology
HTRF
Brand
HTRF
Quantity
1
Therapeutic Area
Oncology & Inflammation
Unit Size
500 Assay Points

Video gallery

How it works

Phospho-CDK2 (Tyr15) assay principle

The Phospho-CDK2 (Tyr15) assay measures CDK2 when phosphorylated at Tyr15. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The assay uses 2 antibodies, one labeled with a donor fluorophore and the other with an acceptor. The first antibody was selected for its specific binding to the phosphorylated motif on the protein, and the second for its ability to recognize the protein independently of its phosphorylation state. Protein phosphorylation enables an immune-complex formation involving both labeled antibodies, and which brings the donor fluorophore into close proximity to the acceptor, thereby generating a FRET signal. Its intensity is directly proportional to the concentration of phosphorylated protein present in the sample, and provides a means of assessing the protein's phosphorylation state under a no-wash assay format.

phospho-CDK2-cellular-kit-1.svg

 

Phospho-CDK2 (Tyr15) two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a 384-well low volume detection plate before the addition of Phospho-CDK2 (Tyr15) HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

 

phospho-CDK2-Tyr15-cellular-kit

 

Phospho-CDK2 (Tyr15) one-plate assay protocol

Detection of Phosphorylated CDK2 (Tyr15) with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

 

phospho-CDK2-Tyr15-cellular-kit

 

Assay validation

Validation of Phospho-CDK2 (Tyr15) assay specificity by siRNA knockdown experiments

HeLa cells were plated in a 96-well plate (40,000 cells/well) and cultured for 24h. The cells were then transfected with siRNAs specific for CDK1, CDK2, CDK4, or CDK6, as well as with a negative control siRNA. Following a 24h incubation, the medium was removed and the cells were treated with 0.5 µg/mL Aphidicolin for 20h. After cell lysis, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF Phospho-CDK2 (Tyr15) detection antibodies were added. The HTRF signal was recorded after an overnight incubation.

Cell transfection with the CDK2 siRNA led to a 92% signal decrease compared to the cells transfected with the negative siRNA. On the contrary, the knockdown of CDK1, CDK4, or CDK6 did not induce any signal decrease, demonstrating that the HTRF Phospho-CDK2 (Tyr15) assay is specific for CDK2 phosphorylation and does not cross-react with other cell cycle CDK family members.

phospho-CDK2-Tyr15-cellular-kit

 

Dephosphorylation of CDK2 Tyr15 by alkaline phosphatase

HeLa cells were cultured in a T175 flask for 48h and treated with 0.5 µg/mL Aphidicolin for 20h. The cells were then lyzed with 3 mL of supplemented lysis buffer #2 (1X) and only a part of the lysate was treated with alkaline phosphatase (AP). For the detection step, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF Phospho-CDK2 (Tyr15) or Total CDK2 detection antibodies were added. The HTRF signal was recorded after an overnight incubation.

As expected, alkaline phosphatase induced the nearly complete dephosphorylation of CDK2 on Tyr15, while the total level of the kinase was not modulated by the treatment.

phospho-CDK2-Tyr15-cellular-kit

 

Phospho-CDK2 (Tyr15) modulation using cell cycle blockers

Human HeLa cells and mouse NIH-3T3 cells were cultured in a 96-well plate (50,000 cells/well) for 24h and then treated for 16h with the cell cycle blockers Aphidicolin and Nocodazole respectively.

After cell lysis, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF Phospho-CDK2 (Tyr15) or Total CDK2 detection antibodies were added. The HTRF signal was recorded after an overnight incubation.

As expected, Aphidicolin (which arrests cells in the early S phase) induced a dose-dependent accumulation of phosphorylated CDK2 at the inhibitory site Tyr15.

Inversely, Nocodazole (which arrests cells at the G2/M border) induced a dose-dependent decrease in CDK2 phosphorylation on Tyr15.

The expression level of the kinase remained relatively stable, whatever the cell treatment.

phospho-CDK2-Tyr15-cellular-kit

 

phospho-CDK2-Tyr15-cellular-kit-8.svg

 

Phospho-CDK2 (Tyr15) inhibition using Wee1 kinase inhibitors

HeLa cells were cultured in a 96-well plate (50,000 cells/well) for 24h and then treated for 2h with the Wee1 kinase inhibitors Adavosertib and PD0166285.

After cell lysis, 16 µL of lysates were transferred into a 384-well low volume white microplate and 4 µL of the HTRF Phospho-CDK2 (Tyr15) or Total CDK2 detection antibodies were added. The HTRF signal was recorded after an overnight incubation.

As expected, both Wee1 kinase inhibitors triggered a dose-dependent decrease in phosphorylated CDK2 at Tyr15, while the expression level of the protein was not modulated by the treatments.

phospho-CDK2-Tyr15-cellular-kit-8.svg

 

phospho-CDK2-Tyr15-cellular-kit

 

HTRF phospho-CDK2 (Tyr15) assay compared to Western Blot

HeLa cells were cultured in a T175 flask in complete culture medium at 37°C-5% CO2. After 48h incubation, the cells were treated with 0.5 µg/mL Aphidicolin for 16h and then lyzed with 3 mL of supplemented lysis buffer #2 (1X) for 30 minutes at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF phospho-CDK2 (Tyr15) detection reagents. Equal amounts of lysates were used for a side by side comparison between HTRF and Western Blot.

Using the HTRF phospho-CDK2 (Tyr15) assay, 800 cells/well were enough to detect a significant signal, while 1,600 cells were needed to obtain a minimal chemiluminescent signal using Western Blot. Therefore in these conditions, the HTRF phospho-CDK2 assay was twice as sensitive as the Western Blot technique

 

phospho-CDK2-Tyr15-cellular-kit

 

Simplified pathway

Role of phospho-CDK2 in the cell-division cycle

CDK2 (Cyclin-Dependent Kinase 2) is a member of the subfamily of CDKs that coordinate cell cycle progression in mammalian cells (including also CDK1, CDK4, and CDK6). CDK2 is activated by interaction with Cyclin E and Cyclin A in the late G1 phase and the S phase respectively, and is also regulated by two major phospho-sites. Phosphorylation at Tyr15 by the kinase Wee1 is inhibitory by preventing ATP binding, whereas Tyr15 dephosphorylation by the phosphatase Cdc25A and phosphorylation at Thr160 by CAK (CDK Activating Kinase) is required for its full activity.

Mitogenic signals, such as growth factors, trigger cells to enter the G1 phase of the cell cycle by inducing cyclin D synthesis, leading to the formation of active CDK4/6-cyclin D complexes. CDK4 and CDK6 mono-phosphorylate the protein of retinoblastoma (RB) which still binds to transcription factor E2F, but some genes can be transcribed, such as cyclin E. In the late G1 and early S phase, Cyclin E interacts with and activates CDK2, which in turn phosphorylates additional sites on RB, resulting in its complete inactivation. The E2F-responsive genes required for S phase progression are thus induced, such as Cyclin A which then interacts with CDK2 to form Cyclin A/CDK2 complexes. CDK2 finally phosphorylates Cdc25B & Cdc25C phosphatases, in turn activating CDK1 which is required for progression in the G2 and M phases of the cell-division cycle.

The activity of CDK2 during the S phase is tightly regulated by opposing positive and negative regulatory influences: CDK2 phosphorylation on Thr160 increases when CDK2 is most active, and at the same time phosphorylation on the inhibitory site Tyr15 is also maximal. The activity of a subpopulation of CDK2 molecules is therefore inhibited at a time in the cell cycle when overall CDK2 activity is increased. Inversely, Tyr15 is abruptly dephosphorylated at mitosis.

CDK2 inhibitory phosphorylation at Tyr15 is essential for maintaining genome integrity and preventing DNA damage during the S phase.

phospho-CDK2-Tyr15-cellular-kit

 

Resources

1-2 of 2 Resources
Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Guide Icon
Guide
Protein degradation awareness in a single guide

An in-depth review of molecular and cellular pathways

The maintenance of proteostasis, the biological mechanisms that control the...

SDS, COAs, Manuals and more Illuminator

SDS, COAs, Manuals and more

Are you looking for technical documents for this product. We have housed them in a dedicated section., click on the links below to explore.

Scroll Icon